D-1278-2019 Class III Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-1278-2019 was initiated by Pfizer Inc. on Apr 29, 2019 and is designated Class III. Reason for recall: Labeling: Label Error on Declared Strength: an artwork error on the secondary packaging of Relpax 40 mg Tablets, indicates that each tablet contains eletriptan hydrobromide equivalent to 20mg… The recall status is terminated (terminated Apr 26, 2021). Affected quantity: 100277 tablets.

Recall details

Product Type
Drugs
Report Date
May 22, 2019
Initiation Date
Apr 29, 2019
Termination Date
Apr 26, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
100277 tablets

Product description

Relpax (eletriptan HBr) 40 mg, a) 12 tablets 2 cards x six 40 mg tablets per blister pack, NDC 0049-2340-05; b) 6 tablets 1 card x six 40 mg tablets per blister pack, NDC 0049-2340-45, Rx Only, Made in Ireland, Distributed by Roerig, Division of Pfizer Inc, NY NY 10017.

Reason for recall

Labeling: Label Error on Declared Strength: an artwork error on the secondary packaging of Relpax 40 mg Tablets, indicates that each tablet contains eletriptan hydrobromide equivalent to 20mg eletriptan, instead of 40mg, on one side of the carton.

Distribution pattern

Nationwide in the USA

Code information

Lot #s: a) W38322, Exp 10/2020, W98482, Exp 03/2021; b) W64062, Exp 01/2021, X27517, Exp 03/2021, AJ3674, Exp 11/2021.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1278-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1278-2019. Report a data issue: hello@regdatalab.com.